Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Clinical Performance of Human Papillomavirus (HPV) Testing versus Cytology for Cervical Cancer Screening: Results of a Large Danish Implementation Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Positive Predictive Value of ICD-10 Diagnosis Codes for COVID-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Identification of Patients with New-Onset Heart Failure and Reduced Ejection Fraction in Danish Administrative Registers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Morbidity as a Predictor for Participation in the Danish National Mammography Screening Program: A Cross-Sectional Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Antidepressant prescriptions and associated factors in men with prostate cancer and their female partners

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Risk of anal high-grade squamous intraepithelial lesions among renal transplant recipients compared with immunocompetent controls

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Human papillomavirus genotype-specific risks for cervical intraepithelial lesions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Expanding our understanding of ovarian cancer risk: the role of incomplete pregnancies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Louise T Thomsen
  • Susanne K Kjær
  • Christian Munk
  • Kirsten Frederiksen
  • Dorthe Ørnskov
  • Marianne Waldstrøm
Vis graf over relationer

Background: Human papillomavirus (HPV) testing is increasingly used as the primary cervical cancer screening test. In a large pilot implementation, we compared participation, referrals and detection of high-grade cervical intraepithelial neoplasia (CIN) in HPV- versus cytology-based cervical cancer screening.

Methods: The implementation was embedded into the routine screening program at Lillebaelt Hospital, Department of Pathology, Vejle, Denmark. Based on the area of residence, women aged 30-59 years were screened by either HPV testing (with HPV16/18 genotyping and cytology triage) or cytology (with HPV triage for minor abnormalities). Our analysis includes women invited or screened during May 2017-May 2018 (invited: n=35,081; screened: n=28,352) with 6 months of follow-up. Information on screening results and sociodemographic characteristics were obtained from registers. Using logistic regression, we estimated odds ratios (ORs) with 95% confidence intervals (CIs) of participation, referral and CIN3+-detection in HPV- versus cytology-based screening, adjusting for sociodemographic characteristics.

Results: Participation was virtually identical in the HPV- and cytology group (58.4% vs 58.8%; ORadjusted=0.97, 95% CI, 0.93-1.01). Referral to colposcopy was more common in the HPV- than cytology group (3.8% vs 2.1%; ORadjusted=1.88, 95% CI, 1.63-2.17). More cases of CIN3+ were detected in the HPV- than cytology group (1.0% vs 0.7%, ORadjusted=1.47; 95% CI, 1.13-1.91).

Conclusion: Participation did not differ between HPV- and cytology-based screening. HPV-based screening detected more cases of CIN3+, but in this initial screening round also led to more colposcopies than cytology-based screening.

OriginalsprogEngelsk
TidsskriftClinical Epidemiology
Vol/bind12
Sider (fra-til)203-213
Antal sider11
ISSN1179-1349
DOI
StatusUdgivet - 2020

Bibliografisk note

Funding Information:
This study was funded by the Lundbeck Foundation (grant no. R287-2018-1454), the Mermaid project (Mermaid 2), and by Lillebaelt Hospital, Region of Southern Denmark.

Funding Information:
HPV tests for this study were provided at reduced cost by Roche. Louise T. Thomsen reports grants from Lundbeck Foundation during the conduct of the study. Susanne K. Kjær has previously received speakers’ fees, advisory board fees and a research grant from Merck, who is the manufacturer of a vaccine against HPV. All other authors declare no potential competing interests.

ID: 61558504